Cell surface expression of activating receptors and co-receptors on peripheral blood NK cells in systemic autoimmune diseases

Scandinavian Journal of Rheumatology

Volumn 41, Issue 4, 2012, Pages 298-304

  Puxeddu, I ^a   Bongiorni, F ^a   Chimenti, D ^a   Bombardieri, S ^a   Moretta, A ^c   Bottino, C ^c,d   Migliorini, P ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR DNAM 1; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER CELL RECEPTOR NKP30; NATURAL KILLER CELL RECEPTOR NKP44; NATURAL KILLER CELL RECEPTOR NKP46; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CD3+ T LYMPHOCYTE; CELL SURFACE; CONTROLLED STUDY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SYSTEMIC AUTOIMMUNE DISORDER; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIGENS, CD3; ANTIGENS, CD56; FEMALE; HUMANS; KILLER CELLS, NATURAL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; RECEPTORS, NATURAL KILLER CELL; SCLERODERMA, SYSTEMIC;

EID: 84863949160     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2011.648657     Document Type: Article

References (42)

1. Shi F, Ljunggren HG, Sarvetnick N. Innate immunity and autoimmunity: from self-protection to self-destruction. Trends Immunol 2001;22:97-101. (Pubitemid 32667529)
2. Middleton D, Curran M, Maxwell L. Natural killer cells and their receptors. Transplant Immunol 2002;10:147-64.
3. Moretta A, Locatelli F, Moretta L. Human NK cells: from HLA class I-specific killer receptors to the therapy of acute leukemias. Immunol Rev 2008;224:58-69.
4. Moretta A, Bottino C, Mingari MC, Biassoni R, Moretta L. What is a natural killer cell? Nat Immunol 2002;3:6-8. (Pubitemid 34065607)
5. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann Rev Immunol 2001;19: 197-223. (Pubitemid 32368034)
6. Sivori S,VitaleM,MorelliL,SanseverinoL,Augugliaro R,BottinoC, et al. p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J ExpMed 1997;186:1129-36. (Pubitemid 27441156)
7. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190:1505-16.
8. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 1998;187:2065-72. (Pubitemid 28285576)
9. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 2000;21:228-34. (Pubitemid 30259028)
10. Bottino C, Castriconi R, Moretta L, Moretta A. Cellular ligands of activating NK receptors. Trends Immunol 2005;26:221-6. (Pubitemid 41556860)
11. Cantoni C, Bottino C, Vitale M, Pessino A, Augugliaro R,Malaspina A, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999;189:787-96.
12. Flodstrom-Tullberg M, Bryceson TY, Shi FD, Hoglund P, Ljunggren HG. Natural killer cells in human autoimmunity. Curr Opin Immunol 2009;21:634-40.
13. Flodstrom M, Shi FD, Sarvetnick N, Ljunggren HG. The natural killer cell - friend or foe in autoimmune disease? Scand J Immunol 2002;55:432-41. (Pubitemid 34451228)
14. Johansson S, Berg L, Hall H, Hoglund P. NK cells: elusive players in autoimmunity. Trends Immunol 2005;26;613-18. (Pubitemid 41726450)
15. Pazmany L. Do NK cells regulate human autoimmunity? Cytokine 2005;32:76-80. (Pubitemid 41563036)
16. Shi FD, van Kaer L. Reciprocal regulation between natural killer cells and autoreactive T cells. Nat Rev Immunol 2006;6:751-60. (Pubitemid 44453461)
17. Perricone R, Perricone C, De Carolis C, Shoenfeld Y. NK cells in autoimmunity: a two-edged weapon of the immune system. Autoimmun Rev 2008;7:384-90.
18. Zhang B Yamamura T, Kondo T, Fujiwara M, Tabira T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J Exp Med 1997;186:1677-87. (Pubitemid 27506281)
19. Fort MM, Leach MW, Rennick DM. A role for NK cells as regulators of CD4+ T cells in a transfer model of colitis. J Immunol 1998;161:3256-61.
20. Maruyama T,WatanabeK, Takei I,KasugaA, ShimadaA,Yanagawa T, et al.Anti-asialoGM1 antibody suppression of cyclophosphamideinduced diabetes in NOD mice.Diabetes Res 1991;17:37-41.
21. Schleinitz N, Vély F, Harlé JR, Vivier E. Natural killer cells in human autoimmune diseases. Immunology 2010;131:451-8.
22. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ 2008;15:226-33.
23. Bellora F, Castriconi R, Dondero A, Reggiardo G, Moretta L, Mantovani A, et al. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci USA 2010;107:21659-64.
24. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
25. Tan EM, Cohen AS, Fries JP, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7. (Pubitemid 13221242)
26. Li WX, Pan HF, Hu JL, Wang CZ, Zhang N, Li J, et al. Assay of T-and NK-cell subsets and the expression of NKG2A and NKG2D in patients with new-onset systemic lupus erythematosus. Clin Rheumatol 2010;29:315-23.
27. Horikawa M, Hasegawa M, Komura K, Hayakawa I, Yanaba K, Matsushita T, et al. Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. J Invest Dermatol 2005;125:731-7.
28. Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM, et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009;60:1753-63.
29. Katz P, Zaytoun AM, Lee JH Jr, Panush RS, Longley S. Abnormal natural killer cell activity in systemic lupus erythematosus: an intrinsic defect in the lytic event. J Immunol 1982;129:1966-71. (Pubitemid 12004352)
30. Sibbitt WL Jr, Mathews PM, Bankhurst AD. Natural killer cell in systemic lupus erythematosus: defects in effector lytic activity and response to interferon and interferon inducers. J Clin Invest 1983;71:1230-9. (Pubitemid 13098909)
31. Yabuhara A, Yang FC, Nakazawa T, Iwasaki Y, Mori T, Koike K, et al. A killing defect of natural killer cells as an underlying immunologic abnormality in childhood systemic lupus erythematosus. J Rheumatol 1996;23:171-7. (Pubitemid 26037216)
32. Ortaldo JR, Mason AT, O'Shea JJ. Receptor-induced death in human natural killer cells: involvement of CD16. J Exp Med 1995;181:339-44.
33. Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors 2010;36:274-88.
34. Green MR, Kennell AS, Larche MJ, Seifert MH, Isenberg DA, Salaman MR. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients. Clin Exp Immunol 2005;141:165-73. (Pubitemid 40904654)
35. Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol 2010;160:348-58.
36. Hafler JP, Maier LM, Cooper JD, Plagnol V, Hinks A, Simmonds MJ, et al. CD226 Gly307Ser association with multiple autoimmune diseases. Genes Immun 2009;10:5-10.
37. Dardalhon V, Schubart AS, Reddy J, Meyers JH, Monney L, Sabatos CA, et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J Immunol. 2005;175:1558-65. (Pubitemid 41023057)
38. ArdolinoM, ZingoniA, Cerboni C, Cecere F, SorianiA, IannittoML, et al. DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA-damage response: relevance for NK-T cell interaction. Blood 2011;117:4778-86.
39. Riccieri V, Parisi G, Spadaro A, Scrivo R, Barone F, Moretti T, et al. Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. J Rheumatol 2005;32:283-6. (Pubitemid 40209126)
40. Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, et al. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009;11:R111.
41. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, Whitfield ML, et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010;5:e12106.
42. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009;11:R147.